ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at Chardan Capital

ProQR Therapeutics (NASDAQ:PRQR)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They presently have a $4.00 price objective on the biopharmaceutical company’s stock. Chardan Capital’s target price would suggest a potential upside of 129.89% from the stock’s current price.

PRQR has been the subject of several other research reports. JMP Securities reiterated a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Monday. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Price Performance

PRQR opened at $1.74 on Friday. The company has a 50 day simple moving average of $2.27 and a two-hundred day simple moving average of $2.62. The firm has a market cap of $142.12 million, a P/E ratio of -5.44 and a beta of 0.24. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. Equities analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth about $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $32,000. Alpine Global Management LLC purchased a new position in ProQR Therapeutics in the fourth quarter worth about $39,000. Two Sigma Securities LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $40,000. Finally, ADAR1 Capital Management LLC purchased a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $54,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).